San Francisco startup Structure Therapeutics is additionally focusing on an oral, as soon as-everyday GLP-1 drug named GSBR-1290—the drug surpassed Wall Avenue’s expectations in June every time a mid-phase study confirmed typical weight loss of close to six% and it ideas to start An additional mid-phase trial in direction of the end of the yr�